Where are they now four years on? A look at the BET/Bromodomain landscape
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
Drugging the undruggable with creative approaches to molecule development
Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?
Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott
With new data on the blood-based TMB test at ESMO, what can we learn about this approach?
A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial
New trends in early drug develoment and Developmental Therapeutics
Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18
Highlights and lowlights from Munich
Highlights and lowlights from Day 2 of #ESMO18
Highlights from Day 1 of #ESMO18 in Munich
The changing face of renal cell cancer from several perspectives
A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...
Third ESMO18 preview on oral abstract presentations
A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.
ESMO18 Preview 1 - Late Breaking Abstracts to watch out for
